Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
darTreg therapy in renal transplantation
NCT02244801Phase 1Completed
- Sponsor
- University of California, San Francisco
- Start
- Apr 2015
- Primary completion
- Sep 2017
- Modality
- Regulatory T Cells (Tregs), Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of darTreg in kidney transplantation, sponsored by University of California, San Francisco. Primary endpoint: Biopsy-confirmed acute rejection at 60 weeks. Started Apr 2015; status: completed.
02
Drugs
darTreg
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT02244801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02244801.